Skip to content
Study details
Enrolling now

MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder

Stephen Robert Marder
NCT IDNCT05790239ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

40

Study length

about 1.1 years

Ages

18+

Locations

2 sites in CA

What this study is about

Researchers are testing whether MDMA-assisted therapy, combined with psychotherapy, is more effective than low dose d-amphetamine-assisted therapy at reducing PTSD symptoms in veterans. The trial will last 395 days and involve approximately 40 participants aged 18 or older who have moderate to severe PTSD.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Participate in Therapy
  • 2.Take 3,4-methylenedioxymethamphetamine
  • 3.Take d-amphetamine

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

dexamfetamine

Endpoints

Primary: Compare changes in PTSD symptom severity in the MDMA vs active control group.

Body systems

Psychiatry / Mental Health